A recent preliminary study suggests GLP-1 receptor agonists (GLP-1 RAs) used for weight loss—such as Ozempic and Wegovy—may be associated with reduced emergency care and other health-care needs among people with chronic migraine compared with those treated with topiramate. The study will be presented at the American Academy of Neurology Annual Meeting (April 18–22, 2026) and has not yet appeared in a peer-reviewed journal.
Key findings
– People with chronic migraine taking GLP-1s were less likely to visit the emergency room in the year after starting treatment (23.7% vs. 26.4% for topiramate).
– GLP-1 users showed about a 10% lower likelihood of ER visits, 14% lower likelihood of hospitalization, and roughly 13% lower likelihood of needing a nerve block or a triptan prescription compared with topiramate users.
– GLP-1 users were also less likely to start additional preventive migraine medications.
– These results are observational and show an association, not proof of causation.
Background
Migraine affects roughly 37 million people in the United States and is one of the world’s most common and disabling conditions. Chronic migraine is defined as headache on 15 or more days per month for more than three months, with migraine features on at least eight of those days.
Study design
Researchers used a health-record database to identify people with chronic migraine who began a GLP-1 medication for other indications (for example, weight loss) within a year of diagnosis, and compared them to patients who started topiramate during the same period. Each group included about 11,000 individuals and was matched on relevant factors to reduce confounding.
Possible mechanisms
Investigators and commentators noted several biologic pathways that could explain the association, though none are proven in humans:
– Anti-inflammatory effects within the trigeminal pain system.
– Reduced intracranial pressure via decreased cerebrospinal fluid secretion.
– Modulation of calcitonin gene–related peptide (CGRP), a key migraine-promoting molecule.
– Weight loss itself has been associated with migraine improvement in patients with obesity, though high-quality randomized controlled trial evidence remains limited.
Cautions and next steps
– Because this is observational data, it cannot establish that GLP-1 RAs treat or prevent migraine. Patients should not seek GLP-1 drugs specifically for migraine outside of clinical trials or established indications.
– Comparisons with topiramate may partly reflect topiramate’s known tolerability and adherence issues rather than a direct pharmacologic advantage of GLP-1 RAs.
– Experts emphasize the need for large, controlled trials to assess efficacy and safety for migraine, particularly in young and middle-aged women who make up the majority of people with migraine.
Migraine management reminders
The goals of migraine care are to relieve symptoms and prevent future attacks. General self-care steps include resting in a quiet, dark room, applying cold to the head, and staying hydrated. Short-term treatments commonly used include triptans, CGRP-targeted drugs, over-the-counter pain relievers (ibuprofen, aspirin, acetaminophen), and antiemetics. Preventive options vary by patient and may include medications and lifestyle strategies.
If you have migraine, discuss treatment options and any interest in new therapies with your health-care professional.
